"...we have a terrific partnership with a company in Poland, WPD Pharmaceuticals. They are a sub licensee for Eastern Europe, and they received a $6 million grant from the EU to conduct two clinical studies of Berubicin, one in a pediatric population with brain cancer and another, basically a mirror study, of Berubicin in adults. That will be an open-label study.
And so, we actually expect interim data from that study as soon as the third quarter of 21. So fairly rapid potential data for a study of this kind. And we’re expecting a pretty rapid patient accrual in Poland because there’s not another competing study in the entire country of 50 million people in GBM, and every single center that treats recurrent GBM in Poland is a site for that study. So we expect them to enroll rapidly, it’s the exact same patient population, same drug supply, same dosing, same CRO, same database, the whole deal. So, the data that we see coming from Poland really will be a very advanced look for investors at how Berubicin is behaving in our study population in the US here.
https://www.docwirenews.com/docwire-pick/...eatment-for-glioblastoma/
|
